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Ethionamide (ETH) is part of the drug arsenal available to treat multi-drug
resistant tuberculosis. The current paradigm of this pro-drug activation involves the
mycobacterial enzyme EthA and the transcriptional repressor, EthR. However, several
lines of evidence suggest the involvement of additional players. The ethA/R locus
was deleted in Mycobacterium bovis BCG and three Mycobacterium tuberculosis
(MTB) strains. While complete resistance to ETH was observed with BCG ethA/R
KO, drug susceptibility and dose-dependent killing were retained in the ethA/R
KO MTB mutants, suggesting the existence of an alternative pathway of ETH
bio-activation in MTB. We further demonstrated that this alternative pathway is EthR-
independent, whereby re-introduction of ethR in ethA/R KO MTB did not lead to
increased resistance to ETH. Consistently, ethA KO MTB (with intact ethR expression)
displayed similar ETH susceptibility profile as their ethA/R KO counterparts. To identify
the alternative ETH bio-activator, spontaneous ETH-resistant mutants were obtained
from ethA/R KO MTB and whole genome sequencing identified single nucleotide
polymorphisms in mshA, involved in mycothiol biosynthesis and previously linked to
ETH resistance. Deletion of mshA in ethA/R KO MTB led to complete ETH resistance,
supporting that the role of MshA in ETH killing is EthA/R-independent. Furthermore
mshA single KO MTB displayed levels of ETH resistance similar or greater than those
obtained with ethA/R KO strains, supporting that mshA is as critical as ethA/R for ETH
killing efficacy.
Keywords: ethionamide, Mycobacterium tuberculosis, multi-drug resistant tuberculosis, mshA, ethA/R locus
INTRODUCTION
Approximately one-third of the world population is presently infected with Mycobacterium
tuberculosis (MTB), and this worldwide epidemic appears to be deteriorating. Underlying this
endemic is the emerging epidemic of multi-drug resistant (MDR-TB) and extensively drug resistant
(XDR-TB) TB strains that have severely undermined control efforts (WHO, 2016). With dwindling
treatment options for MDR and XDR-TB that are decades old, one of the pertinent key issues faced
by the TB research community is the daunting challenge of synthesizing new anti-TB drugs with
novel modes of action (Koul et al., 2011). Since the discovery of Rifampicin (RIF) 40 years ago,
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few promising anti-TB drugs have been discovered, much less
successfully entered the TB clinical pipeline (Singh and Mizrahi,
2016). The recent approval of bedaquiline (BDQ) (Andries et al.,
2005; Diacon et al., 2014; Pym et al., 2016) and delamanid (Gupta
et al., 2016) to treat MDR-TB represents a critical milestone.
However, the emergence of clinical resistance less than 3 years
after BDQ introduction to medical use is likely to limit the impact
of this new TB drug (Bloemberg et al., 2015). Being further
hampered by the unfavorable economics of TB drug development
(Koul et al., 2011), the identification and commercialization of
new anti-TB drugs may take up to another decade. In addition,
more appropriate clinical trials to properly evaluate the efficacy
of anti-TB drugs used in MDR and XDR-TB patient groups are
necessary along with the improvement in TB diagnostics for a
wider coverage of drug susceptibility testing (Koul et al., 2011).
Improving the efficacy of existing drugs may represent an
alternative strategy of choice that should not be disregarded.
This approach, however, necessitates further understanding in
the mechanism of action of mycobacterial drugs and their bio-
activation, especially drugs which have been suggested to have
multiple targets and pathways, such as isoniazid (INH) (Vilchèze
et al., 2006; Vilchèze and Jacobs, 2007) and ethionamide (ETH)
(Morlock et al., 2003).
Despite its clinical use in humans for over 40 years since
its first synthesis in 1956, ETH prescription has been restricted
to patients infected with MDR-TB strains due to its associated
side effects including serious hepatotoxicity, gastro-intestinal
disturbances, and other adverse toxicity issues (Jenner and Smith,
1987). Consequently, this has led to poor patients’ compliance
and unsatisfactory treatment outcome due to drug dosage that
falls within the sub-optimal efficacy range. The recent discovery
of small molecules capable of boosting ETH killing efficacy
supports the idea that it is possible to improve ETH treatment
through dosage reduction, thus minimizing side effects and
improving patient compliance (Willand et al., 2009; Flipo et al.,
2011). As the number of MDR-TB cases climbs, ETH has become
an increasingly important second-line drug for the treatment of
MDR-TB (Vale et al., 2013).
A structural analog of INH, ETH is a thioamide pro-drug
that like INH, inhibits the molecular target InhA, a NADH
specific enoyl-acyl carrier protein reductase, to eventually inhibit
mycolic acid synthesis (Quemard et al., 1992; Banerjee et al.,
1994). However, while both INH and ETH exert inhibitory
actions on InhA, the pathways for pro-drug activation and mode
of action toward their target are distinct (Zhang et al., 1992;
Dessen et al., 1995; Rozwarski et al., 1998; Baulard et al., 2000).
Several lines of experimental evidence point to the Baeyer–
Villiger monooxygenase (BVMO) EthA as the mycobacterial
enzyme responsible for ETH bio-activation (Baulard et al.,
2000; DeBarber et al., 2000; Dover et al., 2007). However,
the physiological role of EthA remains unknown although we
previously reported that it is involved in the cell wall mycolic
acids composition with consequence on the adherence properties
of MTB to mammalian cells (Ang et al., 2014).
In addition to ETH, EthA is a bio-activator of other
thiocarbamide-containing drugs, in particular thiacetazone
(TAC) and isoxyl (ISO), suggesting broad substrate specificity
for this enzyme (Dover et al., 2007). Like ETH, TAC, and ISO
have been shown to target the mycolic acid biosynthesis, albeit
through a different mode of action. The mechanism of action
of TAC remains poorly understood, while ISO as well as its
derivatives were shown to inhibit the synthesis of both fatty acids
and mycolic acid subtypes (Bhowruth et al., 2006).
Specifically, ETH activation by EthA results in the production
of various intermediates and derivative metabolites, among
which the active major compound, ETH∗ has yet to be
structurally identified (Vannelli et al., 2002; Hanoulle et al., 2005,
2006). High resolution magic angle spinning-NMR (HR-NMR)
studies analyzed the distribution of ETH-derived metabolites
inside and outside the bacteria, while monitoring the kinetics
of the drug transformation (Hanoulle et al., 2005). ETH was
found to be metabolized by EthA into ETH-SO and ETH∗,
and subsequently into ETH-OH. Only ETH∗ was observed to
accumulate within the bacterial cells whilst the other ETH
derivatives were exclusively found in the extracellular milieu,
pointing at ETH∗ as the prime active compound candidate
for antibiotic action (Hanoulle et al., 2006). However, due
to the technical challenges to purify ETH∗, its molecular
characterization remains unknown.
Expression of EthA-encoding gene ethA is regulated by the
product of its neighboring gene ethR (Baulard et al., 2000;
DeBarber et al., 2000; Engohang-Ndong et al., 2004), with both
ethA and ethR arranged in a divergent operon with a shared
intergenic promoter region (Figure 1). EthR is a repressor that
belongs to the TetR/CamR family of transcriptional regulators.
Overexpression of ethR resulted in ETH resistance; whereas
chromosomal inactivation of ethR led to ETH hypersensitivity,
suggesting that EthR represses ethA expression in mycobacteria
(Engohang-Ndong et al., 2004). EthR dimers bind cooperatively
as a homo-octamer to the specific operator in the ethA-ethR inter-
genic promoter region, repressing the divergent transcription
of both ethA and ethR (Engohang-Ndong et al., 2004). The
X-ray crystal structure of EthR in a ligand-bound conformation
(EthRHexOc) was reported and described as a homodimer with
a ligand bound to each EthR monomer, the ligand subsequently
being identified as hexadecyl octonoate (HexOc) (Frenois et al.,
2004). In the presence of HexOc, EthRHexOc is unable to bind
to its target DNA and thus fails to repress ethA transcription
(Frenois et al., 2006). This has led to the identification of synthetic
inhibitors of EthR that can improve by up to 10-fold ETH potency
against MTB (Willand et al., 2009), thereby supporting that
boosting ETH bio-activation represents an interesting approach
to improve ETH killing potency without increasing dosage, thus
improving the therapeutic index of ETH.
The identification of a fairly large proportion of ETH-
resistant clinical isolates with no known genes linked to ETH
resistance (Morlock et al., 2003) clearly suggests the existence of
additional factors and pathways involved in ETH bio-activation
and killing efficacy. The mycobacterial serine/threonine protein
kinase PknF was identified to negatively regulate the DNA-
binding activity of EthR via phosphorylation of the EthR homo-
octamer, hence promoting ethA-ethR expression (Leiba et al.,
2014) (Figure 1). This finding suggests that ethA gene expression
is tightly regulated and involves more than one modulator. A few
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FIGURE 1 | The ETH bio-activation paradigm. ETH is activated by the monooxygenase EthA into its activated form, ETH∗. The expression of EthA is regulated by
the transcriptional repressor EthR, and both ethA and ethR are organized in a divergent operon with a shared intergenic promoter region. EthR dimers bind
cooperatively as a homo-octamer to the specific operator in the ethA-ethR intergenic promoter region, repressing both ethA and ethR expression. The mycobacterial
serine/threonine protein kinase PknF negatively regulates the physical binding of EthR to the DNA via phosphorylation of the EthR homo-octamer, hence promoting
ethA-ethR expression. Additionally, the mycothiol synthesis pathway and its end product, mycothiol, have been implicated in ETH bio-activation as well.
years ago, the glycosyltransferase MshA and its downstream
product, mycothiol, the mycobacterial analog for glutathione
have also been proposed to contribute to ETH bio-activation
(Vilchèze et al., 2008, 2011) (Figure 1), although the detailed
molecular mechanisms remain to be elucidated. More recently,
another mycobacterial Baeyer–Villiger monooxygenase, MymA,
was reported to be able to activate ETH, as evidenced by
increased MIC90 of ETH in mymA-overexpressing MTB and
increased resistance to ETH in loss-of-function mymA mutants
(Grant et al., 2016). Even more recently, a cryptic alternative
bio-activation pathway of ETH has been reported which consists
of a bicistronic divergent operon (rv0077c-rv0078) sharing
homologies with the ethA/R locus although no cross-talk between
the two regulons could be demonstrated (Blondiaux et al., 2017).
In this work, we generated ethA/R KO BCG and MTB mutants
and showed that while the BCG KO strain displayed complete
resistance to ETH, drug susceptibility and dose-dependent killing
were retained in the ethA/R KO MTB mutants, thus supporting
the existence of a functional alternative pathway of ETH bio-
activation in MTB that is independent of EthA/R. We further
demonstrated that this alternative pathway is independent of the
transcriptional repressor EthR. Generation of spontaneous ETH-
resistant mutants confirmed a role for MshA in ETH killing
activity in an EthA/R-independent manner.
MATERIALS AND METHODS
Escherichia coli Growth Conditions
All Escherichia coli strains were grown in Luria-Bertani (LB)
broth and agar (Difco). When appropriate, hygromycin and
kanamycin were added at 150 and 50 µg/ml into the
medium, respectively. Chemically competent E. coliTOP10 strain
(Invitrogen) was used for propagation of all plasmids in this
study.
M. bovis BCG and MTB Strains, and
Growth Conditions
Mycobacterium bovis BCG was purchased from ATCC (Pasteur
strain ATCC 35734), while MTB Erdman, H37Rv and CDC1551
strains were a kind gift from Novartis Institute for Tropical
Diseases (NITD), Singapore. All these strains and their derivative
were grown at 37◦C in Middlebrook 7H9 liquid media (Difco)
supplemented with ADS (0.5% bovine serum albumin-fraction V,
0.2% dextrose, 0.085% saline) or with OADC (0.5% bovine serum
albumin-fraction V, 0.2% dextrose, 0.085% saline, 0.005% oleic
acid, and 0.0004% catalase) enrichment as indicated. For growth
on agar, 7H11 (Difco) containing 0.05% Tween 80 (Tw) and
0.2% glycerol supplemented with OADC was used. Appropriate
antibiotics [80 µg/ml hygromycin (Roche), 20 µg/ml kanamycin
(Sigma)] were added when required.
Construction of KO Mutants and
Complemented Strains
The ethA/R locus was deleted by double homologous
recombination as described previously (Bardarov et al., 2002).
Briefly, ∼800 bp-long DNA regions flanking the ethA/R locus in
M. bovis BCG and MTB strains were amplified by polymerase
chain reaction (PCR) and cloned directionally into vector
pYUB854 (Bardarov et al., 2002) with the hygromycin-resistance
cassette (hyg) lying in between the flanking regions. The lacZ
ORF and promoter region from the pGoal17 plasmid (Parish
and Stoker, 2000) were then cloned into the unique PacI site of
the pYUB construct. To prepare electrocompetent mycobacteria,
10 mL cultures were grown to mid-log phase [optical density
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at 600 nm (OD600) of 0.4–0.6] in 7H9-ADS in the absence of
glycerol, followed by culture in fresh 7H9-ADS supplemented
with 1.5% glycine (Sigma) 1 day prior to electroporation. On the
day of electroporation, mycobacteria cells were washed thrice
with 0.05% Tween80 before final resuspension in 1 ml of the same
medium. 200 µl of electrocompetent mycobacteria suspension
were electroporated (2.5 kV, 800 Q, 25 mF) with 2 µg of treated
recombinant plasmid subjected to ultraviolet (UV) treatment
as previously reported (Parish and Stoker, 2000) and plated
onto Hygromycin-containing 7H11 medium supplemented with
40µg/ml X-gal. White hygromycin-resistant clones were selected
after 16 days incubation at 37◦C and screened by PCR with a set
of internal ethA/R primers (5′-TCC AGC GGT TTT CCG CGG
TC-3′ and 5′-TCC CGG TGC GCC ACA TGT TC-3′).
To complement the ethA/R KO mutants, the 2.2 kb ethA/R
full-length locus was PCR amplified (Supplementary Table S1),
cloned into the multiple cloning site of the integrative vector
pMV306 (Stover et al., 1991) and introduced into the genome
of all ethA/R KO mutants via electroporation as described
above. The resulting transformants were plated onto kanamycin-
containing 7H11 agar. After 16 days incubation at 37◦C,
kanamycin-resistant colonies were PCR screened using the
internal ethA/R primers as mentioned above.
The ethA KO and mshA KO mutants were obtained
by double homologous recombination as described above,
whilst complement ethR and complement mshA mutants were
constructed in selected MTB strains using vector pMV306.
Overexpressing ethR mutants were constructed using the
multicopy replicative plasmid pMV262 (Stover et al., 1991).
All plasmid constructs were synthesized and validated using
oligonucleotides listed in Supplementary Table S1.
Construction of the double mshA/ethA/R (m/e) double KO
mutants was obtained by first unmarking the ethA/R KO
mutants in order to remove the hygromycin cassette which was
inserted in place of the ethA/R locus. To do so, the ethA/R KO
mutants were transformed with plasmid pYUB870 which harbors
a χδ-resolvase (tnpR)-encoding gene (Bardarov et al., 2002),
thereby allowing resolvase-mediated cleavage of the hygromycin
cassette. Gentamicin-resistant clones were first selected after
incubation at 31◦C for the resolvase activity and selected again
on 7H11 containing 2% sucrose after incubation at 39◦C. Loss
of the hygromycin cassette and retained deletion of the ethA/R
locus were verified by PCR. Successfully unmarked ethA/R KO
mutants were then used for deletion of mshA by classical double
homologous recombination as described above, followed by
complementation of mshA under the hsp60 promoter and using
pMV306 plasmid (Supplementary Table S1).
Southern Blot Analysis
1–3 µg of genomic DNA (gDNA) was digested with SacI
(Promega), separated on a 1.5% agarose gel and treated
as previously reported (Sambrook and Russell, 2001). DNA
was transferred onto a Millipore Immobilon-Ny+ Transfer
membrane and UV cross-linked. For detection of ethA/R and
ethA KO mutants, a 415 bp DIG-labeled probe was amplified
using a set of primers that bind approximately 1.5 kb downstream
of ethR, 5′-TGA GTT TAG TTG GGA CCT AGG CC-3′and
5′-CTA GAG TCA CAT CAG AAA CAT TTG A-3′. For
detection of mshA and double mshA/ethA/R KO mutants, a
600 bp DIG-labeled probe was amplified using a set of primers
that bind immediately upstream of mshA, 5′-CCC GTC CAC
TCT GAA ATG CTC G-3′ and 5′-ATC AAC CCT GAA CCG
TCA TCG TGT-3′. Probe amplifications were done via PCR
according to the manufacturer’s instructions (DIG-labeling kit,
Roche). Hybridization and signal detection were performed
using a detection kit (Roche) according to the manufacturer’s
protocol. EasyHyb (Roche) was used as the pre-hybridization
and hybridization solutions, and CSPD (Roche) was used as the
detection substrate for chemical luminescence.
In Vitro Drug Susceptibility Assays
Bacterial drug susceptibility assays were performed in 7H9
media supplemented with either ADS or OADC (as indicated
in the figure legends) as described previously (Kurabachew
et al., 2008). ETH (Sigma), ISO (NITD), and TAC (NITD) were
dissolved in 90% DMSO, whilst INH (Sigma) was dissolved in
ultrapure water for stock solutions. Using a broth microdilution
method, INH and ETH were twofold serially diluted (0.02–5 and
0.3–80 µM respectively) in 7H9 medium in 96-well flat bottom
plates. Log phase MTB cultures were diluted in 7H9-OADC or
7H9-ADS medium to obtain ∼2 × 105 colony forming units
(CFUs)/ml. 100 µl of the bacterial inoculum were added to
each well-containing an equal volume of drug suspension. The
plates were then incubated for 5–7 days at 37◦C. On the 5th
or 7th day (as indicated), OD600 was measured using a Biorad
iMark Microplate absorbance reader and curves were plotted
using PRISM to determine the minimal inhibitory concentration
(MIC50) values. The MIC50 is defined as the lowest concentration
of drug that is required to inhibit 50% growth of the MTB strain
compared to growth obtained in drug-free 7H9 medium. Drug
assays were performed thrice independently. After determining
the MIC50 values, 50 µl of the bacterial suspensions incubated
at 1x, 2x, and 4x MIC50 were plated onto 7H11 agar plates. CFU
were enumerated after 16 days incubation at 37◦C and the CFU-
based MIC90 range (in µM) was defined as the range of drug
concentrations within which the number of CFUs compared to
the drug free control was reduced by 90% (1 log reduction).
Isolation of ETH-resistant Spontaneous
Mutants
To generate spontaneous ETHR clones from the Erdman ethA/R
KO mutant, a protocol was adapted from both Luria and
Delbrück (1943) and Mathys et al. (2009). Since the Erdman
ethA/R KO mutant displays low resistance to ETH, optimization
was performed to determine the appropriate ETH concentration
range that would minimize background and false positive.
Eventually, 360, 420, and 480 µM ETH were selected as
appropriate ETH concentrations.
To generate spontaneous ETHR mutants, an exponential
phase 7H9-ADS liquid culture (OD600 of 0.6–0.8) of the ethA/R
KO mutant was used to inoculate three individual flasks of 7H9-
ADS medium at an initial OD600 of 0.005–0.01. The cultures
were incubated for 1–2 weeks. An estimated 108 and 107 bacteria
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were then plated onto 7H11 plates containing selected ETH
concentrations. ETHR colonies were picked and grown in liquid
medium for gDNA extraction and glycerol stocks. The MIC of
ETH was determined for these clones, and extracted gDNA was
used for whole genome sequencing (WGS).
Whole Genome Sequencing (WGS) of
ETHR Mutants
Library Building
Two ug of gDNA was fragmented to a peak size range of
200–400 bp using Covaris S2 (Covaris, Woburn, MA, USA)
(shearing conditions – Duty cycle: 20%; Intensity: 4; Cycles
per burst: 200; Time: 360 s). The fragmented samples were
then purified (Qiagen PCR purification kit; Qiagen, Valencia,
CA, USA), and quality-checked (2100 Bioanalyzer on a DNA
1000 Chip, Agilent Technologies, Santa Clara, CA, USA). The
whole genome library was prepared using Illumina’s TruSeq
DNA Sample Preparation Kit, v2 (part number 15026486)
according to the manufacturer’s instructions. Fragments in the
range 300–500 bp were selected on a Pipen Prep from Sage
Science, and quality-checked. Finally, using the Multiplexing
Sample Preparation Oligonucleotide Kit (Illumina, San Diego,
CA, USA), samples underwent 14 PCR cycles followed by
Agencourt AMPure XP magnetic bead (Beckman Coulter, Brea,
CA, USA) clean up according to the manufacturer’s instructions.
qPCR was then performed using LightCycler 480 SYBR Green I
Master mix (Roche Applied Science, Indianapolis, IN, USA) in
a LightCycler R© 480 II real time thermal cycler (Roche Applied
Science, Indianapolis, IN, USA) according to the manufacturer’s
instructions.
Multiplexed Sequencing
Next generation sequencing (NGS) was done using Illumina
Hiseq 2000 flow cell, 2 × 76 base pair-end runs. PhiX was used
as control.
Analysis of Whole Genome Sequences
Unix Korn Shell1 was used to access the server and perform the
quality control of raw reads (fastq files) and file transfer.
Statistical Analysis
Unless otherwise stated, bars represent means + standard
deviations (SD) and averages were compared using a
bidirectional unpaired Student’s t-test with a 5% significance
level (∗p ≤ 0.05).
RESULTS
MTB Remains Susceptible to ETH
Despite Removal of the ethA/R Locus
The ethA/R locus was removed and substituted in place
by the hygromycin-resistant cassette hyg in M. bovis BCG
and three MTB backgrounds, namely Erdman, H37Rv and
CDC1551 (Supplementary Figure S1). The minimum inhibitory
1http://www.kornshell.com/doc/
concentration of drug required to inhibit 50% growth of
mycobacteria compared to drug-free control (MIC50) was
measured for the respective ethA/R KO mutant strains in order
to determine their level of resistance to ETH and to the two
other thiocarbamide-containing drugs ISO and TAC. INH was
included as well as a negative control since bio-activation of INH
is not EthA/R-dependent. Consistently, all ethA/R KO mutants
displayed parental susceptibility to INH (Table 1). In contrast,
and as expected, removal of the ethA/R locus in M. bovis BCG
led to complete resistance to ETH (Table 1 and Supplementary
Figure S2). However, complete resistance to ETH was not seen
with the MTB ethA/R KO mutants whereby a dose-dependent
killing could still be observed as evidenced by the sigmoidal MIC
curves obtained (Supplementary Figure S2). The MIC50 values
measured with the ethA/R KO MTB mutants were increased by
2–3X compared to their respective parental strains (Table 1).
Furthermore, all the ethA/R KO mutant strains displayed
increased resistance to TAC, with MIC50 values increasing by
2–8X (Table 1). As for ISO, with the exception of Erdman
ethA/R KO mutant which was found slightly more resistant
with a twofold increase in the MIC50 value compared to its
parental counterpart, no significant changes in MIC50 were
observed with the other mutant strains. Importantly, parental
susceptibility to the three drugs was restored in each strain upon
re-introduction of the ethA/R locus (Table 1 and Supplementary
Figure S2).
To confirm the MIC50 data obtained, the bacterial suspensions
incubated with ETH concentrations that corresponded to 1x,
2x, and 4x MIC50 were plated for CFU enumeration. The
ETH concentration range within which a 90% reduction of the
bacteria load (also equivalent to 1 log) compared to drug-free
control was determined and called CFU-based MIC90. Consistent
with the MIC50 data, while BCG ethA/R KO displayed full
resistance to ETH, dose-dependent killing was observed with all
three MTB KO strains over the range of ETH concentrations
assayed (Supplementary Figure S3). The MIC90 range of ETH
on CDC1551 ethA/R KO mutant was increased by 8–16
fold compared to its parental and complemented counterparts
(Table 2). In contrast, a mild twofold increase in ETH MIC90 was
observed with ethA/R KO H37Rv and Erdman strains compared
to their parental and complemented counterparts. Although
these three MTB strains belong to the same Lineage 4 (Euro-
American), H37Rv and Erdman are considered as laboratory
strains whereas CDC1551 is regarded as a “clinical” strain.
The extensive passages in vitro are likely to result in genetic
changes that may lead to distinct phenotypes both in vitro
and in vivo when compared to CDC1551, including the drug
susceptibility profile (Betts et al., 2000; Coscolla and Gagneux,
2010).
Altogether, these data show that although the ETH MICs
values obtained for ethA/R KO MTB strains were higher
than those measured with the corresponding parental and
complemented strains, ETH susceptibility and dose-dependent
drug response to ETH were retained. In particular both MTB
Erdman and H37Rv strains remained very susceptible to ETH
upon deletion of ethA/R locus with 3- and 2-fold increases in
their MIC values respectively. The retained susceptibility to ETH
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TABLE 1 | MIC50 of ETH in BCG and M. tuberculosis parental and mutant strains.
Strain INH ETH ISO TAC
BCG 0.38 15.86 3.93 0.76
BCG ethA/R KO 0.35 NA 3.85 5.91
BCG ethA/R KO complement ethA/R 0.39 14.49 4.04 0.27
CDC1551 0.22 6.90 12.40 9.20
CDC1551 ethA/R KO 0.22 12.40 11.56 19.28
CDC1551 ethA/R KO complement ethA/R 0.20 4.77 14.00 6.42
Erdman 0.15 3.89 10.87 4.80
Erdman ethA/R KO 0.11 9.29 21.20 12.12
Erdman ethA/R KO complement ethA/R 0.12 3.25 13.75 2.07
H37Rv 0.20 3.30 13.08 2.0
H37Rv ethA/R KO 0.20 9.16 10.67 12.32
H37Rv ethA/R KO complement ethA/R 0.19 3.10 11.59 1.47
MIC50 concentrations are indicated in µM. NA, not available due to complete ETH resistance.
TABLE 2 | CFU-based MIC90 of ETH in BCG and M. tuberculosis parental and mutant strains.
Parental strain ethA/R KO ethA/R KO complement ethA/R pMV262-ethR pMV306-ethR ethA KO
BCG 10–20 NA 10–20 ND ND ND
CDC1551 2.5–5 40 2.5–5 20–40 ND 20–40
Erdman 1.25–2.5 2.5–5 1.25–2.5 1.25–2.5 2.5–5 1.25–2.5
H37Rv 1.25–2.5 2.5–5 1.25–2.5 2.5–5 ND 2.5–5
Bacterial suspensions corresponding to 1x, 2x, and 4x MIC50 were plated onto 7H11 agar plates. CFU were enumerated after 16 days incubation at 37◦C and the
CFU-based MIC90 range (in µM) was determined. pMV262-ethR was introduced into WT MTB strains. pMV306-ethR was introduced into ethA/R KO Erdman strain.
ND, not determined; DF, drug-free; NA, not available due to complete resistance to the drug.
despite removal of ethA/R in the three MTB strains suggests that
the pro-drug ETH still gets activated into its bactericidal form in
an EthA-independent manner, thus supporting the existence of
an alternative bio-activation pathway for ETH in MTB.
The Alternative Pathway of ETH
Bio-activation in MTB Is Not under the
Control of the Transcriptional Repressor
EthR
To further investigate the possible existence of an alternative
pathway of ETH bio-activation in MTB, we questioned whether
the transcriptional repressor EthR which negatively modulates
the ethA/R locus, would also modulate this alternative pathway.
Indeed, using programs available online2, EthR was predicted
to bind to a number of promoter regions in addition to
the ethA/R intergenic region. Thus it is conceivable that
in WT MTB, EthR may repress the expression of another
gene that is involved in ETH bio-activation. To address this
hypothesis, the ethR open reading frame (ORF) was over-
expressed in all three WT MTB strains under the control
of the constitutive strong promoter hsp60 and using the
multicopy replicative plasmid pMV262. Real-time PCR analysis
confirmed the over-expression of ethR (8–16 fold increase)
in comparison to the parental strains. Over-expression of
ethR in these three strains was expected to lead to the
strong repression of ethA as well as any other genes that
2http://genome.tbdb.org/tbdb_sysbio/Resources.html
may be negatively regulated by EthR. Therefore, should an
alternative EthR-dependent pathway of ETH bio-activation
exist in MTB, susceptibility to ETH would be affected when
ethR is over-expressed. However, the ethR over-expressing
MTB strains retained ETH susceptibility in a dose-dependent
manner (Supplementary Figures S4A–C) and displayed CFU-
based MIC90 values similar to those obtained with the
ethA/R KO mutants (Table 2). These results thus support the
existence of an alternative pathway of ETH bio-activation in
MTB and indicate that this pathway is likely to be EthR-
independent.
To confirm this observation, ethA single KO mutants were
generated in the three MTB backgrounds. We reasoned that
should EthR negatively repress the alternative ETH bio-activation
pathway, ethA KO mutants would display full or increased
resistance to ETH compared to their corresponding ethA/R KO
counterparts. Results indicated that the CFU-based MIC90 ranges
obtained with ethA single KO mutants were similar to the values
obtained with the ethA/R KO mutants (Table 2), thus further
supporting that the alternative pathway of ETH bio-activation is
not negatively regulated by EthR.
Finally, ethR was re-introduced into the Erdman ethA/R KO
mutant using integrative plasmid pMV306. We postulated that
expression of ethR in the ethA/R KO mutant would only impact
the susceptibility to ETH if the alternative pathway of ETH
bio-activation is negatively regulated by EthR. However, ETH
susceptibility was retained in this strain (Supplementary Figure
S4D) and the MIC90 range was similar to that obtained with the
ethA/R KO counterpart (Table 2).
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Altogether, these findings strongly support the existence of an
EthA/R-independent alternative pathway of ETH bio-activation
in MTB strains.
ETHR Spontaneous Mutants Display
Mutations in the mshA Locus
In order to identify the molecular players that are involved
in the alternative pathway of ETH bio-activation in MTB,
spontaneous mutants that were highly resistant to ETH were
generated from the Erdman ethA/R KO mutant. Briefly, Erdman
ethA/R KO bacteria were plated onto agar plates containing a
range of ETH concentrations (360–480 µM). Two independent
rounds of ETHR mutants were generated. Individual ETH-
resistant (ETHR) colonies were picked and sub-cultured. Drug
susceptibility assays were then carried out for these ETHR clones
to confirm ETH resistance. No MIC50 values could be derived
for these mutants as all mutants grew uninhibitedly even at
the highest concentration of ETH (80 µM) tested (data not
shown).
Since InhA is the downstream target of both ETH and
INH (Banerjee et al., 1994; Vilchèze et al., 2005), a pre-screen
was first conducted to exclude all the ETHR spontaneous
mutants harboring mutation(s) in the inhA gene. Previous
literature has shown that the INH MICs obtained with most
MTB isolates harboring mutations in inhA promoter region
and ORF were usually low (>1 µg/ml) (Ramaswamy et al.,
2003); hence, susceptibility to INH was assayed by growing the
ETHR clones in the presence of INH at 1 µg/ml (or 7.29 µM)
and turbidity was visually assessed after 10 days incubation.
For the great majority of the clones (∼90%) obvious turbidity
was observed, indicating that these clones were INHR thereby
suggesting the presence of a mutation in their inhA locus.
However, seven clones displayed impaired growth in the presence
of 7.29 µM INH and further independent drug susceptibility
assays indicated that these clones displayed varying levels of
resistance to INH with MIC50 values ranging between 0.625
and 1.25 µM, with the exception of one clone displaying an
unusually high level of INH resistance (5 µM). Sequencing
revealed that there was no mutation in the inhA ORF and
promoter region for each of the seven clones analyzed (data not
shown).
The seven ETHR clones were then subjected to WGS and
compared against the Erdman ethA/R KO parental genome.
Numerous mutations came up upon WGS, but the list was
restricted to insertion/deletions (INDELs) and non-synonymous
SNPs (NS-SNPs), and further refined by eliminating NS-SNPs
that resulted in conservative amino acid changes (i.e., change
to an amino acid with similar physiochemical properties).
Strikingly, NS-SNPs were found in mshA for six out of the seven
clones analyzed (Supplementary Table S2). Apart from mshA,
mutations were found in other genes candidates as well, a large
proportion of which are involved in metabolism pathways (galE3,
cobD, plcB, and pks5). Another group of gene candidates included
gltx, recD, and topA involved in the transcriptional, translational,
and nucleotide assembly pathways (Supplementary Table S2).
The remaining identified genes Erdman_1484 and Erdman_0263
could not be categorized under any pathways and these genes
remained unclassified.
Since six out of the seven clones analyzed by WGS displayed
a mutation in the mshA locus, we decided to further investigate
the contribution of this gene in ETH bio-activation. MshA
is a glycosyltransferase involved in mycothiol biosynthesis, an
equivalent to the antioxidant glutathione in mammals, and was
found to be essential for ETH susceptibility in MTB (Vilchèze
et al., 2008). Furthermore, mshA mutations were shown to
confer varying levels of co-resistance to INH and ETH in
M. bovis (Vilchèze et al., 2011). Consistently, a recent study
reported that 45.6% of ETHR MDR-TB isolates harbored a
mutation in mshA (Rueda et al., 2015). However, the role of
the glycosyltransferase MshA in ETH-mediated killing has yet to
be deciphered. The identification of ETHR ethA/R KO Erdman
mutants with mutations in mshA here further supports the role
of MshA in ETH killing efficacy and suggests that it may be in an
ethA/R-independent fashion.
Construction and Growth Kinetic of
MshA-deficient Mutants
To validate the role of MshA in ETH bio-activation, the mshA
locus was deleted from WT MTB Erdman, H37Rv and CDC1551
strains, thus generating mshA single KO mutants. Furthermore,
mshA was also deleted in the corresponding ethA/R KO mutants,
giving rise to mshA ethA/R (m/e) double KO mutants. All
clones were verified by Southern blot (Supplementary Figure S5)
and subsequently complemented by introducing the hsp60-mshA
construct into the mycobacterial genome using the integrative
plasmid pMV306. Our choice to express mshA under hsp60
promoter was driven by the fact that the mshA promoter has yet
to be characterized and delineated.
Growth defect was previously reported for MshA-deficient
MTB mutants (Vilchèze et al., 2008). Consistently, mshA and
m/e KO mutants displayed a significant growth defect in 7H9
supplemented with ADS (Figures 2A–C). In contrast, all the
KO strains grew well in 7H9-OADC (Figures 2D–F). However,
it is worth to note that mshA and m/e KO mutants in the
CDC1551 background still displayed a slight but significant and
reproducible growth defect compared to their respective parental
counterpart (Figure 2F).
Given that mshA and m/e KO mutants are unable to grow
on 7H9-ADS, drug susceptibility assays involving these mutants
were performed in 7H9-OADC. However, since the initial MIC
values obtained in this work were generated in 7H9-ADS
(Supplementary Figure S2), we re-established their MIC in 7H9-
OADC. The MIC50 values obtained for INH were comparable
regardless of the medium supplement (OADC or ADS) for the
three MTB backgrounds (WT and ethA/R KO) (Supplementary
Table S3). Similar MIC values for ETH were also observed with
the three WT MTB strains in both types of medium. However, the
ETH MICs increased by twofold for all ethA/R KO mutants upon
replacing ADS with OADC (Supplementary Table S3). Despite
the greater resistance to ETH in the presence of OADC, dose-
dependent drug susceptibility to ETH was nevertheless retained
(data not shown). Therefore, our data indicated that although
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FIGURE 2 | In vitro growth kinetics of mshA KO and mshA ethA/R (m/e) double KO mutants. Growth kinetics of Erdman (A,D), H37Rv (B,E), CDC1551
(C,F) parental, mshA KO and mshA/ethA/R (m/e) double KO strains in 7H9 media supplemented with ADS (A–C) or OADC (D–F) over a period of 14 days. Every
2–3 days, OD600 was measured. The experiment was repeated twice independently.
some variation exists between the MIC values when using ADS
or OADC as supplement, ETH susceptibility was still retained in
the ethA/R KO MTB mutants.
mshA Deletion Leads to ETH Resistance
Drug susceptibility assays were conducted with the mshA single
KO and mshA ethA/R (m/e) double KO mutants. The slower
growth rates observed with the CDC1551 mshA and m/e KO
mutants (Figure 2F) were taken into consideration by reading the
plates at day 7 post-setup.
Remarkably, the combined absence of both ethA/R and mshA
loci in all three MTB backgrounds abrogated ETH susceptibility,
rendering the m/e double KO mutants completely resistant to
ETH (Supplementary Figure S6 and Table 3). MIC50 values
could not be obtained for these mutants since mycobacteria grew
uninhibitedly even at the highest concentration of ETH (80 µM)
tested (Table 3). These observations were supported by the lack
of a dose-response curve with all three m/e KO mutant strains
(Supplementary Figure S6). Re-introduction of mshA in the m/e
KO mutants restored ETH susceptibility to levels similar to those
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TABLE 3 | MIC50 of INH and ETH on mshA single KO and mshA ethA/R
double KO mutants.
Strain MIC50 INH MIC50 ETH
CDC1551 0.26 7.18
CDC1551 ethA/R KO 0.2 31.04
CDC1551 ethA/R KO complement ethA/R 0.29 5.12
CDC1551 mshA KO 0.98 NA
CDC1551 mshA KO complement mshA 0.43 11.82
CDC1551 m/e KO 0.57 NA
CDC1551 m/e KO complement m/e 0.30 4.76
Erdman 0.18 3.04
Erdman ethA/R KO 0.18 19.69
Erdman ethA/R KO complement ethA/R 0.17 2.67
Erdman mshA KO 0.49 20.63
Erdman mshA complement mshA 0.28 5.42
Erdman m/e KO 0.37 NA
Erdman m/e KO complement m/e 0.20 13.54
H37Rv 0.20 3.30
H37Rv ethA/R KO 0.28 12.55
H37Rv ethA/R KO complement ethA/R 0.23 1.99
H37Rv mshA KO 0.85 40.67
H37Rv mshA KO complement mshA 0.28 12.89
H37Rv m/e KO 0.80 NA
H37Rv m/e KO complement m/e 0.27 11.12
Drug susceptibility assays were performed in 7H9-OADC. MIC50 are indicated in
µM. NA, not available due to complete ETH resistance.
observed with their respective ethA/R KO counterparts (Table 3).
Thus, these data indicate that the combined removal of mshA
and ethA/R loci in MTB leads to complete resistance to ETH, and
further confirms the involvement of mshA in ETH killing efficacy.
Interestingly, deletion of mshA alone led to MIC50 values
either comparable (Erdman background) or greater (H37Rv and
CDC1551 backgrounds) than those obtained with their ethA/R
KO counterparts (Supplementary Figure S6 and Table 3). This
observation thus suggests that mshA is at least as critical as
ethA/R for ETH killing efficacy. Complementation with mshA
only partially restored the levels of ETH susceptibility, possibly
due to the usage of hsp60 promoter in place of its native promoter.
Additionally, and consistent with previous report (Vilchèze
et al., 2008, 2011), the mshA KO mutants displayed mild
increased resistance to INH with a twofold (Erdman) and
fourfold (H37Rv and CDC1551) increase of the MIC50 values
compared to the parental strains (Table 3).
Together, these data confirm the contribution of mshA in ETH
and (to a lower extent) INH killing efficacy in MTB. In addition,
the complete resistance to ETH upon deletion of mshA from
ethA/R KO mutants suggests that the role of MshA in ETH killing
efficacy is independent on EthA/R-mediated ETH bio-activation.
DISCUSSION
Previous studies had provided indirect experimental evidence
of the involvement of EthA/R in ETH bio-activation either
through over-expression of ethA or ethR, or through ethR
deletion in M. bovis BCG (Baulard et al., 2000; DeBarber et al.,
2000). Here, we show for the first time that deletion of the
entire ethA/R locus in BCG led to full resistance to ETH, thus
demonstrating the critical role of ethA/R in ETH bio-activation
in BCG. However, deletion of ethA/R in MTB strains led to
a mild increase only in their levels of resistance to ETH. In
fact, susceptibility and dose-dependent drug response to ETH
were retained in these ethA/R KO MTB mutants. Previous
studies involving anti-mycobacterial pro-drugs INH and PZA
have shown that absence of their respective bio-activators in MTB
led to extremely high to complete levels of resistance (Heym
et al., 1993; Morlock et al., 2000; Ng et al., 2004). The reported
MICs of INH for katG-deleted mutants and KatG-deficient MTB
isolates (∼80 mg/ml) (Heym et al., 1993) were 400-fold higher
than the MIC measured with their WT and complemented
counterparts (∼0.02 mg/ml), proving that deletion of katG is
sufficient to confer high level of resistance to INH (Ng et al.,
2004). Similarly, PZA-resistant strains with mutations in pncA
that led to a loss in pyrazinamidase activity also displayed high
levels of resistance to PZA, ranging from 100 to more than
800µg/ml versus 12.5µg/ml in WT counterparts (Morlock et al.,
2000). Arguably, in the absence of their respective enzymatic bio-
activator to convert these pro-drugs into a catalytically active
form, these stable and chemically inert drug forms are expected
to remain inactive and non-bactericidal, thus accounting for the
high to complete levels of drug resistance observed. Previous
studies by Hanoulle et al. (2006) have shown that ETH is
metabolized into an ETH-S-oxide derivate (ETH-SO) and ETH∗,
and subsequently into ETH-OH; out of which only ETH∗ was
observed to accumulate within the bacterial cells. On the other
hand, ETH, ETH-SO and ETH-OH were found exclusively in
the extracellular milieu, suggesting ETH∗ to be the prime active
compound candidate for antibiotic action. Other than ETH∗,
all other ETH derivatives including pro-drug ETH itself possess
little or no anti-mycobactericidal activity (Baulard et al., 2000;
DeBarber et al., 2000; Vannelli et al., 2002; Francois et al., 2009).
Here, the fact that deletion of the ethA/R locus did not lead to
high level of resistance to ETH in MTB challenges the paradigm
according to which ethA/R locus is solely responsible for ETH
bio-activation in MTB (Baulard et al., 2000; DeBarber et al., 2000)
and led us to propose the existence of a functional alternative
pathway of ETH bio-activation independent of the ethA/R locus.
This alternative pathway of ETH bio-activation that is
functional in MTB but not in BCG is likely to be distinct from the
cryptic operon (rv0077c-rv0078) recently reported by Blondiaux
et al. (2017), which is only expressed in the presence of small
molecules that inhibit the EthR-like repressor (Rv0078), thereby
allowing expression of ethA2 gene (rv0077c) which encodes an
EthA-like monooxigenase capable of activating ETH.
In fact, the genome of MTB encodes more than 30 putative
monooxygenases which may have stemmed from evolution as
a protective mechanism against various xenobiotic substances,
leading Morlock et al. (2003) to propose the existence of one or
more enzymes with functional redundancy to EthA. Consistently,
five other putative BVMO-encoding genes have been previously
reported in mycobacteria (Fraaije et al., 2004; Bonsor et al.,
2006). The broad substrate specificity for BMVOs such as EthA
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(Fraaije et al., 2004) may support that one or more of these
enzymes are capable of compensating for the loss of EthA
for ETH activation function in MTB. Consistently, a recent
study reported a role for BVMO MymA (Rv3083) in ETH
activation (Grant et al., 2016). It is thus possible that the retained
susceptibility to ETH observed in the MTB ethA/R KO strains
is due to the presence of MymA, whereas MymA in BCG
would be non-functional. A BLAST analysis3 indeed revealed
two NS-SNPs in mymA (Rv3083) (I81A and V94I) between the
MTB strains and BCG. However, both NS-SNPs map outside
the ‘Baeyer–Villigerase’ (BVase) motif which is involved in the
enzymatic activity of the protein (Bonsor et al., 2006). Therefore,
we believe that these NS-SNPs are unlikely to account for a
possible difference in the enzymatic activity of MymA between
MTB and BCG. Further study is required in order to test the
possible involvement of MymA in the differential susceptibility
to ETH in BCG and MTB ethA/R KO mutants.
Among ETHR MTB clinical isolates that have been reported,
up to 20–50% harbor no mutations in genes known to be
involved in ETH resistance (Morlock et al., 2003), adverting
that the mechanisms involved in ETH killing efficacy involve
additional players. To identify the mycobacterial factors involved
in ETH bio-activation, we generated spontaneous ETHR mutants
from the ethA/R KO Erdman strain. Among the different gene
candidates identified by WGS, mshA came out in six out of the
seven clones analyzed. mshA mutations have been associated to
resistance to INH (Jagielski et al., 2014, 2015) and ETH (Rueda
et al., 2015) in clinical isolates. In addition, mshA mutations were
shown to confer varying levels of co-resistance to INH and ETH
in MTB (Vilchèze et al., 2008). Previous work has suggested that
mycothiol, the final product of MshA pathway, plays a role in
the EthA-mediated bio-activation steps of ETH (Vilchèze et al.,
2008). Here, we demonstrated that removal of mshA in ethA/R
KO MTB led to full resistance to ETH, thereby suggesting that
the role of mycothiol in ETH killing efficacy is independent of,
or at least not limited to, its interaction with EthA and may also
be involved in the alternative pathway of ETH bio-activation,
perhaps by interacting with the alternative BVMO MymA for
example (Grant et al., 2016). Alternatively, MshA and mycothiol
could play a role in ETH killing efficacy downstream ETH bio-
activation. The fact that mshA deletion/mutations also affect the
susceptibility to INH supports this latter hypothesis, since ETH
and INH target the same molecule, InhA, through a comparable
mechanism via the formation of a NAD-drug (INH/ETH) adduct.
It is thus plausible that MshA activity plays a role during one
of these common steps. We propose that mycothiol may either
stabilize the formation of ETH∗ or form a complex with ETH∗.
Additional experiments are necessary to further decipher the
role of mycothiol in this process. Previous studies found that
EthA is able to metabolize thiacetazone into either a sulfenic acid
intermediate under acidic/neutral conditions or a carbodiimide
metabolite under basic conditions; and both metabolites readily
react with glutathione (GSH) to either regenerate the parent
drug or form a GSH-adduct, respectively (Qian and Ortiz de
Montellano, 2006). Since mycothiol is the mycobacterial analog
3http://blast.ncbi.nlm.nih.gov/Blast.cgi
for GSH, and EthA has also been shown to oxidize ETH into a
sulfenic acid metabolite (Vannelli et al., 2002), ETH metabolites
could react with mycothiol in a similar manner. Consequently,
one could further speculate that such a reaction would either
stabilize these reactive ETH metabolites or help in drug recycling,
or perhaps lower the intracellular concentration of mycothiol
thus sensitizing mycobacteria to oxidative damage, or culminate
in a combination of all three consequences.
Whole genome sequencing analysis of the ETHR spontaneous
mutants has identified several other genes that may deserve
further investigation. Of particular interest, Erdman_1484, a
gene encoding for thioredoxin was identified. Interestingly,
in Streptomyces coelicolour, the amount of mycothiol has
been shown to be under the control of a sigma factor σR,
which is regulated by an anti-sigma factor RsrA via a thiol-
disulphide redox switch involving thioredoxin (Park and Roe,
2008); One could speculate that such thiol-disulphide redox
switch exists in mycobacteria as well, which could affect
mycothiol levels, subsequently influencing the susceptibility to
ETH killing. Moreover, since mycobacterial thioredoxins have
been demonstrated to serve regulatory functions as disulphide
reductants that affect the metabolism of mycobacteria (Van
Laer et al., 2012; Machová et al., 2014), characterization of this
gene may provide further insights into ETH killing efficacy.
Additionally, since small thiol molecules do not appear to be
directly associated with the thioredoxin system in bacteria unlike
that in mammalian cells (Gustafsson et al., 2012), one could
also speculate that thioredoxin may facilitate redox reactions
specifically involved in the alternative pathway of ETH bio-
activation.
CONCLUSION
The data generated in this work provides the experimental
evidence of the existence of a functional alternative pathway
of ETH bio-activation in MTB that is independent of the
ethA/R locus. Furthermore, they confirm the importance of
MshA pathway and mycothiol in ETH killing efficacy, and may
suggest a role of this pathway at a later step, after formation
of the ETH cidal metabolite, ETH∗. Hence, together with the
recent discovery of an alternative BVMO (MymA) capable of
activating ETH (Grant et al., 2016), and a cryptic alternative
pathway of ETH bio-activation (Blondiaux et al., 2017), our
findings underscore the complexity and possible redundancy of
the mechanisms involved in ETH bio-activation in pathogenic
mycobacteria. Greater understanding of these mechanisms and
their possible cross-talks are necessary in order to rationally
design intervention strategies to improve ETH killing efficacy.
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